These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33935948)

  • 1. Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis.
    Proschmann U; Inojosa H; Akgün K; Ziemssen T
    Front Neurol; 2021; 12():650530. PubMed ID: 33935948
    [No Abstract]   [Full Text] [Related]  

  • 2. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.
    Bava CI; Valentino P; Malucchi S; Bottero R; Martire S; Sapio AD; Bertolotto A
    Mult Scler Relat Disord; 2024 Aug; 88():105748. PubMed ID: 38959590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
    Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
    EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Johnsson M; Farman HH; Blennow K; Zetterberg H; Malmeström C; Axelsson M; Lycke J
    Mult Scler; 2022 Nov; 28(13):2070-2080. PubMed ID: 35856574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
    Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation.
    Proschmann U; Haase R; Inojosa H; Akgün K; Ziemssen T
    Front Immunol; 2021; 12():715195. PubMed ID: 34512637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients.
    Bridel C; Verberk IMW; Heijst JJA; Killestein J; Teunissen CE
    Mult Scler Relat Disord; 2021 Jan; 47():102666. PubMed ID: 33291033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
    Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders.
    Balasa R; Bianca C; Septimiu V; Iunius S; Adina H; Sebastian A; Andreea R; Anca M; Smaranda M
    CNS Neurol Disord Drug Targets; 2018; 17(6):464-472. PubMed ID: 29968546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
    van Lierop ZY; Noteboom S; Steenwijk MD; van Dam M; Toorop AA; van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Teunissen CE; Killestein J
    Mult Scler; 2022 Dec; 28(14):2231-2242. PubMed ID: 36062492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?
    Havla J; Kleiter I; Kümpfel T
    Ther Clin Risk Manag; 2013; 9():361-9. PubMed ID: 24124371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC
    Neurology; 2017 Oct; 89(15):1584-1593. PubMed ID: 28916537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.
    Sehr T; Proschmann U; Thomas K; Marggraf M; Straube E; Reichmann H; Chan A; Ziemssen T
    J Neuroinflammation; 2016 Jun; 13(1):164. PubMed ID: 27349895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum neurofilament light chains in assessing the course of multiple sclerosis].
    Kamenskikh EM; Alifirova VM; Pashkovskaya DV; Titova MA; Koroleva ES; Levchuk LA; Ivanova SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(1):89-93. PubMed ID: 38261289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.
    Akgün K; Kretschmann N; Haase R; Proschmann U; Kitzler HH; Reichmann H; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e555. PubMed ID: 31119188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.